Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers.

Glover ED, Laflin MT, Schuh KJ, Schuh LM, Nides M, Christen AG, Glover PN, Strnad JV.

Addiction. 2007 May;102(5):795-802.

PMID:
17506156
[PubMed - indexed for MEDLINE]
2.

Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.

Weinberger AH, Sacco KA, Creeden CL, Vessicchio JC, Jatlow PI, George TP.

Schizophr Res. 2007 Mar;91(1-3):217-25. Epub 2007 Feb 9.

PMID:
17293085
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms.

George TP, Termine A, Sacco KA, Allen TM, Reutenauer E, Vessicchio JC, Duncan EJ.

Schizophr Res. 2006 Oct;87(1-3):307-15. Epub 2006 Jul 18.

PMID:
16854565
[PubMed - indexed for MEDLINE]
4.

Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Kalman D, Morissette SB, George TP.

Am J Addict. 2005 Mar-Apr;14(2):106-23. Review.

PMID:
16019961
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect.

Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL.

Schizophr Res. 2005 Nov 15;79(2-3):323-35. Epub 2005 Jun 14.

PMID:
15961287
[PubMed - indexed for MEDLINE]
6.

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP.

Arch Gen Psychiatry. 2005 Jun;62(6):649-59.

PMID:
15939842
[PubMed - indexed for MEDLINE]
7.

Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls.

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM.

Drug Alcohol Depend. 2005 Nov 1;80(2):259-65.

PMID:
15869844
[PubMed - indexed for MEDLINE]
8.

Mecamylamine moderates cue-induced emotional responses in smokers.

McClernon FJ, Rose JE.

Addict Behav. 2005 May;30(4):741-53.

PMID:
15833578
[PubMed - indexed for MEDLINE]
9.

Smoking cue reactivity in schizophrenia: effects of a nicotinic receptor antagonist.

Fonder MA, Sacco KA, Termine A, Boland BS, Seyal AA, Dudas MM, Vessicchio JC, George TP.

Biol Psychiatry. 2005 Apr 1;57(7):802-8.

PMID:
15820238
[PubMed - indexed for MEDLINE]
10.

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.

Sacco KA, Bannon KL, George TP.

J Psychopharmacol. 2004 Dec;18(4):457-74. Review.

PMID:
15582913
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Mecamylamine acutely increases human intravenous nicotine self-administration.

Rose JE, Behm FM, Westman EC, Bates JE.

Pharmacol Biochem Behav. 2003 Sep;76(2):307-13.

PMID:
14592683
[PubMed - indexed for MEDLINE]
12.

Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking.

Rose JE, Behm FM, Westman EC.

Pharmacol Biochem Behav. 2001 Feb;68(2):187-97.

PMID:
11267622
[PubMed - indexed for MEDLINE]
13.

Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings.

Cox LS, Tiffany ST, Christen AG.

Nicotine Tob Res. 2001 Feb;3(1):7-16.

PMID:
11260806
[PubMed - indexed for MEDLINE]
14.

Mecamylamine increases cigarette smoking in psychiatric patients.

Marx CE, McIntosh E, Wilson WH, McEvoy JP.

J Clin Psychopharmacol. 2000 Dec;20(6):706-7. No abstract available.

PMID:
11106149
[PubMed - indexed for MEDLINE]
15.

Smoking and mental illness: A population-based prevalence study.

Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH.

JAMA. 2000 Nov 22-29;284(20):2606-10.

PMID:
11086367
[PubMed - indexed for MEDLINE]
16.

Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization.

George TP, Verrico CD, Picciotto MR, Roth RH.

J Pharmacol Exp Ther. 2000 Oct;295(1):58-66.

PMID:
10991961
[PubMed - indexed for MEDLINE]
Free Article
17.

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Dalack GW, Healy DJ, Meador-Woodruff JH.

Am J Psychiatry. 1998 Nov;155(11):1490-501. Review.

PMID:
9812108
[PubMed - indexed for MEDLINE]
18.

Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

Olincy A, Young DA, Freedman R.

Biol Psychiatry. 1997 Jul 1;42(1):1-5.

PMID:
9193735
[PubMed - indexed for MEDLINE]
19.

Mecamylamine does not precipitate withdrawal in cigarette smokers.

Eissenberg T, Griffiths RR, Stitzer ML.

Psychopharmacology (Berl). 1996 Oct;127(4):328-36.

PMID:
8923568
[PubMed - indexed for MEDLINE]
20.

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.

Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV.

Clin Pharmacol Ther. 1994 Jul;56(1):86-99.

PMID:
8033499
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk